本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Ultragenyx Pharmaceutical Inc

12.94
-0.1320-1.01%
成交量:236.68萬
成交額:3,072.69萬
市值:12.72億
市盈率:-2.22
高:13.22
開:13.07
低:12.87
收:13.07
52周最高:39.89
52周最低:12.87
股本:9,831.72萬
流通股本:8,071.56萬
量比:0.62
換手率:2.93%
股息:- -
股息率:- -
每股收益(TTM):-5.8279
每股收益(LYR):-5.8316
淨資產收益率:-608.47%
總資產收益率:-24.22%
市淨率:-4.37
市盈率(LYR):-2.22

資料載入中...

2021/05/04

重要事件披露

8-K - Current report
2021/04/16

重要事件披露

8-K - Current report
2021/02/16

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/16

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/16

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/16

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/12

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2021/02/12

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2021/02/12

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/11

重要事件披露

8-K - Current report
2021/02/10

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/01

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/01/21

重要事件披露

8-K - Current report
2021/01/11

重要事件披露

8-K - Current report
2021/01/08

重要事件披露

8-K - Current report
2020/12/17

重要事件披露

8-K - Current report
2020/12/10

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2020/12/07

重要事件披露

8-K - Current report
2020/11/06

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2020/11/02

重要事件披露

8-K - Current report